<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116842</url>
  </required_header>
  <id_info>
    <org_study_id>AN10/9307</org_study_id>
    <secondary_id>2010-020020-21</secondary_id>
    <secondary_id>11730</secondary_id>
    <nct_id>NCT02116842</nct_id>
  </id_info>
  <brief_title>Minimum Effective Dose (MED) &amp; Epidural Bupivacaine</brief_title>
  <official_title>Comparison of the ED95 Dose of 0.075% and 0.1% Bupivacaine for Labour Analgesia in Primigravida.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Academic Anaesthesia (NIAA), UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Obstetric Anaethetists' Association (OAA), UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Local anaesthetics are highly toxic drugs. They can cause toxicity by an absolute overdose,
      accidental injection in a blood vessel or slow absorption from the area of injection. The
      risk of toxicity when performing regional anaesthesia can be reduced significantly by
      injecting the optimal dose of local anaesthetic at the correct site.

      To date most of the local anaesthetic dose finding studies for epidural labour analgesia has
      focused on ED50 ( the dose effective in 50% of patients). The purpose of this research study
      is to find out the ED95 dose (the dose effective in 95% of patients) of local anaesthetic for
      epidural analgesia in labour.

      The dose determined from this research trial will guide the anaesthetists to the optimal
      starting dose of the local anaesthetics for epidural analgesia in labour. This would lead to
      decreased chances of toxicity and will improve patient safety.

      We aim to recruit a total of 100 pregnant patients in early labour (cervical dilatation ≤ 5
      cm) requesting epidural analgesia to answer the research question based on the continual
      reassessment method. Patients will be recruited according to well-defined criteria. They will
      be fully informed about the study and have the choice of not participating or opting out at
      any time during the study. It is not going to affect the kind of treatment they receive. The
      experts in the field with full safety precautions will perform this study at St James'
      Hospitals, Leeds.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective dose in 95% of patients (ED95) dose of bupivacaine for a primigravida in early labour.</measure>
    <time_frame>up to 30 minutes</time_frame>
    <description>To find out the ED95 dose of bupivacaine 0.075% and 0.1% for epidural analgesia for a primigravida in early labour .</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pregnancy</condition>
  <condition>Labour</condition>
  <condition>Primigravida Labour</condition>
  <condition>Epidural Block</condition>
  <arm_group>
    <arm_group_label>0.075% bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consenting patients randomised to receive 0.075% bupivacaine and 40 µg fentanyl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consenting patients randomised to receive 0.1% bupivacaine and 40 µg fentanyl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% bupivacaine</intervention_name>
    <description>Epidural block in early labour.</description>
    <arm_group_label>0.1% bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.075% bupivacaine</intervention_name>
    <description>Epidural block in early labour.</description>
    <arm_group_label>0.075% bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 µg fentanyl</intervention_name>
    <description>Given with different doses of bupivacaine in epidural block.</description>
    <arm_group_label>0.075% bupivacaine</arm_group_label>
    <arm_group_label>0.1% bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anaesthesiologists (ASA) 1-3 patients

          -  Primigravida (1st pregnancy) patients requesting epidural analgesia in early labour (≤
             5 cm cervical dilatation.

        Exclusion Criteria:

          -  Primigravida (1st pregnancy) patients requesting epidural analgesia in late labour (&gt;
             5 cm cervical dilatation)

          -  Multigravida patients ( ≥ 2nd pregnancy)

          -  ASA &gt; 3

          -  Allergy to Bupivacaine

          -  Unable to give written informed consent

          -  BMI &gt;35

          -  Abnormal blood coagulation profile

          -  Patients taking any medication that are indicated in the Summary of Product
             Characteristics (SPC) as not recommended
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Philip M Hopkins</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leeds</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neville Young</last_name>
    <phone>44 113 392 6459</phone>
    <email>neville.young@leedsth.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leeds Sponsor Office Quality Assurance Department</last_name>
    <phone>44 113 392 2878</phone>
    <email>r&amp;d@leedsth.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Sandeep Varma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2014</study_first_submitted>
  <study_first_submitted_qc>April 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <last_update_submitted>April 16, 2014</last_update_submitted>
  <last_update_submitted_qc>April 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Neville Young</investigator_full_name>
    <investigator_title>Sponsor Quality Assurance Manager</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

